Sanctuary Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Sanctuary Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,557	Closed	-$41.4K	–	2916
2026 Q1	$41.4K	Sell	11,557 -5,880	-34%	-$23.4K	﹤0.01%	2499
2025 Q4	$61.2K	Buy	17,437 +6,769	+63%	+$23.2K	﹤0.01%	2371
2025 Q3	$34.8K	Sell	10,668 -53,017	-83%	-$167K	﹤0.01%	2396
2025 Q2	$156K	Buy	+63,685	New	+$323K	﹤0.01%	2213

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Sanctuary Advisors's RCKT Position: Q2 2026 in Review

Sanctuary Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q2 2026, closing a stake of 11,557 shares — an estimated $41.4K sold.

Sanctuary Advisors first reported a position in RCKT in Q2 2025 and held it in 4 quarters. The position peaked at $156K in Q2 2025. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

Sanctuary Advisors reported no remaining Rocket Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Sanctuary Advisors sold 11,557 Rocket Pharmaceuticals shares in Q2 2026, an estimated $41.4K.
Sanctuary Advisors first reported a position in Rocket Pharmaceuticals in Q2 2025 and held it in 4 quarters.
Sanctuary Advisors's Rocket Pharmaceuticals position peaked at $156K in Q2 2025.
180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Sanctuary Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.